New Age Alpha Advisors LLC Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

New Age Alpha Advisors LLC bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, HoldingsChannel.com reports. The firm bought 16,023 shares of the company’s stock, valued at approximately $190,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Nordea Investment Management AB grew its stake in shares of Roivant Sciences by 22.5% in the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after purchasing an additional 52,031 shares during the period. Barclays PLC raised its stake in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after acquiring an additional 75,609 shares in the last quarter. Retirement Systems of Alabama lifted its holdings in shares of Roivant Sciences by 26.9% during the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the period. Elevate Capital Advisors LLC acquired a new stake in shares of Roivant Sciences in the 4th quarter valued at $2,116,000. Finally, State Street Corp grew its holdings in shares of Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after purchasing an additional 1,118,561 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction on Monday, January 13th. The stock was bought at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the transaction, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the transaction, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,395,541 shares of company stock worth $15,028,538 over the last three months. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Price Performance

ROIV opened at $10.08 on Thursday. The stock has a market capitalization of $7.19 billion, a P/E ratio of -67.20 and a beta of 1.26. The company’s 50 day simple moving average is $10.67 and its 200-day simple moving average is $11.36. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several analyst reports. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $17.10.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.